Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Immunology

What is the Connection Between MCAS, POTS, and EDS?

At a Glance

MCAS, POTS, and Ehlers-Danlos Syndrome (EDS) frequently occur together in what doctors call the 'trifecta.' Their overlapping symptoms require objective laboratory proof, like the 20% + 2 tryptase blood test during a flare, to accurately diagnose MCAS and properly guide treatment.

If your doctor is evaluating you for Mast Cell Activation Syndrome (MCAS), they may also ask about your joint flexibility or monitor your heart rate when you stand up. This is because MCAS is frequently found alongside two other conditions: Postural Orthostatic Tachycardia Syndrome (POTS) and Ehlers-Danlos Syndrome (EDS) (specifically the hypermobile type, hEDS).

In medical communities, the frequent co-occurrence of these three conditions is often referred to as the “trifecta” [1][2]. While researchers are still investigating exactly why they cluster together, the clinical overlap is well-recognized, with symptoms from one condition often triggering or worsening the others [3][4].

How the Conditions Interact

The exact biological link connecting the trifecta is complex and not fully understood, but current hypotheses focus on how the conditions physically affect each other [5]:

  • EDS (Ehlers-Danlos Syndrome) is a group of connective tissue disorders that cause joint hypermobility and overly stretchy tissues. This laxity in connective tissue can cause blood vessels to be overly compliant, leading to blood pooling in your lower body [6][7].
  • POTS (Postural Orthostatic Tachycardia Syndrome) is a form of dysautonomia (dysfunction of the autonomic nervous system). When you stand up, your heart rate spikes—typically increasing by 30 beats per minute or more within 10 minutes—to compensate for blood pooling [5].
  • MCAS (Mast Cell Activation Syndrome) involves hyperactive mast cells that inappropriately release chemical mediators like histamine. These mediators can alter blood vessel tone and increase inflammation, which can further aggravate the dizziness and rapid heart rate seen in POTS [8].

While POTS symptoms are largely triggered by changes in posture (like standing up), MCAS flares are often driven by external environmental triggers such as heat, stress, certain foods, or chemicals [9][10].

Understanding Different Types of Mast Cell Issues

When investigating mast cell problems, your doctor will need to determine if your mast cells are genetically abnormal. This is the difference between clonal and standard (non-clonal) conditions:

  • MMCAS (Monoclonal Mast Cell Activation Syndrome) & Systemic Mastocytosis (SM): These are “clonal” disorders, meaning there is a specific genetic mutation within the mast cells themselves—most commonly the KIT D816V mutation [11][12]. Doctors use highly sensitive blood tests or bone marrow biopsies to check for these specific markers [13][14].
  • MCAS (Non-clonal/Idiopathic): In standard MCAS, the mast cells do not have these specific genetic mutations, but they are still hyper-reactive and release mediators inappropriately [15][16].

The Challenge and Importance of Objective Diagnosis

Because the symptoms of MCAS, POTS, and EDS overlap so heavily, they can easily mimic one another [1][17]. For example, a sudden rapid heart rate, dizziness, and intense flushing could be an autonomic response caused by POTS, or it could be the result of a sudden histamine release from mast cells [18][19]. Severe gastrointestinal issues are also a hallmark of all three conditions [20][21].

Because symptoms alone cannot accurately distinguish between a POTS flare and an MCAS flare, medical consensus strictly requires objective laboratory proof to officially diagnose MCAS [22][23]. While gathering this proof can be incredibly frustrating and anxiety-inducing for patients—because chemical markers degrade quickly and are notoriously difficult to catch—this strict testing protects you from being misdiagnosed.

To confirm that symptoms are truly driven by mast cell degranulation, doctors look for a specific rise in chemical markers:

  • The “20% + 2” Tryptase Rule: Your doctor will test your baseline serum tryptase (when you feel normal) and test it again during a severe symptom flare. To diagnose MCAS, the flare level must be at least 20% higher than your baseline, plus an additional 2 ng/mL [10][24]. Crucially, this blood draw must happen between 1 and 4 hours after your symptoms start, which requires careful logistical planning with your doctor [23].
  • Urine Mediators: If tryptase does not rise or if you miss the narrow time window, doctors may test for 24-hour urinary metabolites of other mast cell mediators, such as prostaglandins and leukotrienes [25][26].

Who Manages the Trifecta?

Because these conditions affect the joints, the autonomic nervous system, and the immune system, treating the trifecta requires a multidisciplinary approach. You may need a team that includes a rheumatologist (for EDS), a cardiologist or neurologist (for POTS), and an allergist or immunologist (for MCAS). Coordinating care between these specialists ensures that treatments for one condition do not inadvertently aggravate another.

Common questions in this guide

Why do MCAS, POTS, and EDS often occur together?
While the exact biological link is complex, the physical effects of these conditions interact. Connective tissue laxity from EDS can cause blood pooling, triggering the rapid heart rate of POTS. Hyperactive mast cells in MCAS release chemicals that alter blood vessel tone, worsening POTS symptoms.
How do doctors tell the difference between a POTS flare and an MCAS flare?
Because symptoms like dizziness, rapid heart rate, and intense flushing overlap heavily, doctors cannot rely on symptoms alone. They require objective laboratory proof, such as a documented rise in tryptase or urine mediators during an active flare, to officially diagnose MCAS.
What is the 20% + 2 tryptase rule?
The '20% + 2' rule is a diagnostic standard for MCAS that involves comparing your baseline tryptase blood level to your level during a severe flare. To confirm MCAS, the flare level must be at least 20% higher than your baseline plus an additional 2 ng/mL, drawn 1 to 4 hours after symptoms start.
What kind of doctors treat the MCAS, POTS, and EDS trifecta?
Because this 'trifecta' affects connective tissue, the autonomic nervous system, and the immune system, you will likely need a multidisciplinary care team. This typically includes a rheumatologist for EDS, a cardiologist or neurologist for POTS, and an allergist or immunologist for MCAS.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the logistical plan for getting my tryptase levels drawn within the strict 1-to-4-hour window during my next major flare? Can you provide a standing lab order so I can go straight to a lab or ER?
  2. 2.How can we work together to distinguish whether my rapid heart rate and dizziness are being triggered by postural changes (POTS) or environmental factors (MCAS)?
  3. 3.Do you recommend specialized testing to rule out the KIT D816V mutation and monoclonal mast cell conditions?
  4. 4.Who should act as the primary coordinator of my care team if I need to balance treatments between a cardiologist, rheumatologist, and allergist?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does MCAS Progress to Systemic Mastocytosis or Cancer?Do Antihistamines Mean I Have MCAS? | Inciteful MedHow Do I Get a Tryptase Blood Test During an MCAS Flare?How to Take Medications When Allergic to Pill FillersIs a Bone Marrow Biopsy Required to Diagnose MCAS?Is a Strict Low-Histamine Diet Necessary for MCAS?What Does an Idiopathic MCAS Diagnosis Mean?What's the Difference Between MCAS and Traditional Allergies?Why Does MCAS Cause Sudden Anxiety and Panic Attacks?

References

References (26)
  1. 1

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  2. 2

    An overview of Ehlers Danlos syndrome and the link between postural orthostatic tachycardia syndrome and gastrointestinal symptoms with a focus on gastroparesis.

    Wu W, Ho V

    Frontiers in neurology 2024; (15()):1379646 doi:10.3389/fneur.2024.1379646.

    PMID: 39268060
  3. 3

    Comorbidities and neurosurgical interventions in a cohort with connective tissue disorders.

    Ruhoy IS, Bolognese PA, Rosenblum JS, et al.

    Frontiers in neurology 2024; (15()):1484504 doi:10.3389/fneur.2024.1484504.

    PMID: 39931100
  4. 4

    Idiopathic osteoporosis, Ehlers-Danlos syndrome, postural orthostatic tachycardia syndrome, and mast cell activation disorder in a 27-year-old male patient: A unique case presentation.

    Rattray C

    Clinical case reports 2022; (10(5)):e05887 doi:10.1002/ccr3.5887.

    PMID: 35600027
  5. 5

    Association between Ehlers-Danlos syndrome and mast cell activation syndrome: Is there scientific evidence?

    Cuenca-Gómez JA, Dawid-Milner MS, Sánchez-Martínez R

    Revista clinica espanola 2026; (226(2)):502457 doi:10.1016/j.rceng.2026.502457.

    PMID: 41554340
  6. 6

    Decoding the Genetic Basis of Mast Cell Hypersensitivity and Infection Risk in Hypermobile Ehlers-Danlos Syndrome.

    Shirvani P, Shirvani A, Holick MF

    Current issues in molecular biology 2024; (46(10)):11613-11629 doi:10.3390/cimb46100689.

    PMID: 39451569
  7. 7

    Mechanobiology in the Comorbidities of Ehlers Danlos Syndrome.

    Royer SP, Han SJ

    Frontiers in cell and developmental biology 2022; (10()):874840 doi:10.3389/fcell.2022.874840.

    PMID: 35547807
  8. 8

    Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome.

    Roma M, Marden CL, De Wandele I, et al.

    Autonomic neuroscience : basic & clinical 2018; (215()):89-96 doi:10.1016/j.autneu.2018.02.006.

    PMID: 29519641
  9. 9

    Autonomic function testing and symptom severity in patients with suspected mast cell activation disorders.

    Stino AM, Nelson J, Gutgsell O, et al.

    Autonomic neuroscience : basic & clinical 2025; (262()):103362 doi:10.1016/j.autneu.2025.103362.

    PMID: 41265079
  10. 10

    Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.

    Buttgereit T, Gu S, Carneiro-Leão L, et al.

    Allergy 2022; (77(9)):2794-2802 doi:10.1111/all.15304.

    PMID: 35364617
  11. 11

    Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified.

    Ballul T, Sabato V, Valent P, et al.

    EClinicalMedicine 2025; (80()):103043 doi:10.1016/j.eclinm.2024.103043.

    PMID: 39877259
  12. 12

    A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

    Carter MC, Desai A, Komarow HD, et al.

    The Journal of allergy and clinical immunology 2018; (141(1)):180-188.e3 doi:10.1016/j.jaci.2017.05.036.

    PMID: 28629749
  13. 13

    High-sensitivity KIT D816V variation analysis by droplet digital polymerase chain reaction: The reference laboratory perspective.

    Shean RC, Hellwig S, Saadalla A, et al.

    American journal of clinical pathology 2025; (164(2)):145-149 doi:10.1093/ajcp/aqaf008.

    PMID: 40036308
  14. 14

    Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.

    Reichard KK, Chen D, Pardanani A, et al.

    American journal of clinical pathology 2015; (144(3)):493-502 doi:10.1309/AJCPSGQ71GJQQACL.

    PMID: 26276780
  15. 15

    Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

    Akin C, Gülen T, Castells MC, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):19-28 doi:10.1016/j.jaip.2025.10.046.

    PMID: 41285202
  16. 16

    Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis.

    Weiler CR

    The journal of allergy and clinical immunology. In practice 2020; (8(2)):498-506 doi:10.1016/j.jaip.2019.08.022.

    PMID: 31470118
  17. 17

    Complex Presentations, Identification and Treatment of Mast Cell Activation Syndrome and Associated Conditions: A Case Report.

    Quinn AM

    Integrative medicine (Encinitas, Calif.) 2023; (22(4)):36-41.

    PMID: 37752934
  18. 18

    Hives in autonomic disorders: a cutaneous marker of a distinct symptom phenotype.

    Savigamin C, Chung T, Rebman AW, et al.

    Annals of medicine 2026; (58(1)):2626224 doi:10.1080/07853890.2026.2626224.

    PMID: 41668453
  19. 19

    Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.

    Weinstock LB, Afrin LB, Reiersen AM, et al.

    Brain, behavior, & immunity - health 2025; (48()):101048 doi:10.1016/j.bbih.2025.101048.

    PMID: 40686928
  20. 20

    Symptoms of mast cell activation syndrome in functional gastrointestinal disorders.

    Wilder-Smith CH, Drewes AM, Materna A, Olesen SS

    Scandinavian journal of gastroenterology 2019; (54(11)):1322-1325 doi:10.1080/00365521.2019.1686059.

    PMID: 31687861
  21. 21

    Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders.

    Kurin M, Elangovan A, Alikhan MM, et al.

    Neurogastroenterology and motility 2022; (34(5)):e14265 doi:10.1111/nmo.14265.

    PMID: 34535952
  22. 22

    The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome.

    Wang E, Ganti T, Vaou E, Hohler A

    Allergy and asthma proceedings 2021; (42(3)):243-246 doi:10.2500/aap.2021.42.210022.

    PMID: 33980338
  23. 23

    Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach.

    Lee E, Picard M

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):49 doi:10.1186/s13223-025-00998-9.

    PMID: 41272881
  24. 24

    Diagnosis of mast cell activation syndrome: a global "consensus-2".

    Afrin LB, Ackerley MB, Bluestein LS, et al.

    Diagnosis (Berlin, Germany) 2021; (8(2)):137-152 doi:10.1515/dx-2020-0005.

    PMID: 32324159
  25. 25

    Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.

    Butterfield JH

    The journal of allergy and clinical immunology. In practice 2022; (10(8)):1974-1984 doi:10.1016/j.jaip.2022.03.008.

    PMID: 35346887
  26. 26

    Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management.

    Hamilton MJ

    Current gastroenterology reports 2024; (26(4)):107-114 doi:10.1007/s11894-024-00924-w.

    PMID: 38353900

This page explains the connection between MCAS, POTS, and EDS for educational purposes only. Always consult a multidisciplinary healthcare team for proper diagnosis, lab testing, and condition management.

Get notified when new evidence is published on Mast Cell Activation Syndrome (MCAS).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.